REFERENCES
1. Sampath V, Abrams EM, Adlou B, et al. Food allergy across the globe.J Allergy Clin Immunol. 2021;148(6):1347-1364.
2. Gupta RS, Warren CM, Smith BM, et al. The Public Health Impact of
Parent-Reported Childhood Food Allergies in the United States.Pediatrics. 2018;142(6).
3. Gupta RS, Warren CM, Smith BM, et al. Prevalence and Severity of Food
Allergies Among US Adults. JAMA Netw Open. 2019;2(1):e185630.
4. Grabenhenrich L, Trendelenburg V, Bellach J, et al. Frequency of food
allergy in school-aged children in eight European countries-The
EuroPrevall-iFAAM birth cohort. Allergy. 2020;75(9):2294-2308.
5. DunnGalvin A, Blumchen K, Timmermans F, et al. APPEAL-1: A
multiple-country European survey assessing the psychosocial impact of
peanut allergy. Allergy. 2020;75(11):2899-2908.
6. Jakobsen LS, Pilegaard K, Pires SM, Bogh KL. The disease burden of
peanut allergy in Denmark measured by disability-adjusted life years
(DALYs). Allergy. 2021;76(5):1583-1585.
7. Lieberman JA, Gupta RS, Knibb RC, et al. The global burden of illness
of peanut allergy: A comprehensive literature review. Allergy.2021;76(5):1367-1384.
8. Fernandez-Rivas M, Vereda A, Vickery BP, et al. Open-label follow-on
study evaluating the efficacy, safety, and quality of life with extended
daily oral immunotherapy in children with peanut allergy.Allergy. 2022;77(3):991-1003.
9. Nurmatov U, Dhami S, Arasi S, et al. Allergen immunotherapy for
IgE-mediated food allergy: a systematic review and meta-analysis.Allergy. 2017;72(8):1133-1147.
10. Phelps A, Bruton K, Grydziuszko E, Koenig JFE, Jordana M. The Road
Toward Transformative Treatments for Food Allergy. Front Allergy.2022;3:826623.
11. Al Hawi Y, Nagao M, Furuya K, et al. Agreement Between Predictive,
Allergen-Specific IgE Values Assessed by ImmunoCAP and IMMULITE 2000
3gAllergy Assay Systems for Milk and Wheat Allergies. Allergy
Asthma Immunol Res. 2021;13(1):141-153.
12. Goyard S, Balbino B, Chinthrajah RS, et al. A highly sensitive
bioluminescent method for measuring allergen-specific IgE in microliter
samples. Allergy. 2020;75(11):2952-2956.
13. Suarez-Farinas M, Suprun M, Kearney P, et al. Accurate and
reproducible diagnosis of peanut allergy using epitope mapping.Allergy. 2021;76(12):3789-3797.
14. Santos AF, Alpan O, Hoffmann HJ. Basophil activation test:
Mechanisms and considerations for use in clinical trials and clinical
practice. Allergy. 2021;76(8):2420-2432.
15. Duan L, Celik A, Hoang JA, et al. Basophil activation test shows
high accuracy in the diagnosis of peanut and tree nut allergy: The
Markers of Nut Allergy Study. Allergy. 2021;76(6):1800-1812.
16. Decuyper, II, Pascal M, Van Gasse AL, et al. Performance of basophil
activation test and specific IgG4 as diagnostic tools in nonspecific
lipid transfer protein allergy: Antwerp-Barcelona comparison.Allergy. 2020;75(3):616-624.
17. Santos AF, Bergmann M, Brough HA, et al. Basophil Activation Test
Reduces Oral Food Challenges to Nuts and Sesame. J Allergy Clin
Immunol Pract. 2021;9(5):2016-2027 e2016.
18. Alpan O, Layhadi JA, Ulrik Sonder S, Li H, Shamji MH. Basophil
activation test: A diagnostic, predictive and monitoring assay for
allergen immunotherapy. Allergy. 2021;76(5):1321-1324.
19. Chinthrajah RS, Purington N, Andorf S, et al. Sustained outcomes in
oral immunotherapy for peanut allergy (POISED study): a large,
randomised, double-blind, placebo-controlled, phase 2 study.Lancet. 2019;394(10207):1437-1449.
20. Tsai M, Mukai K, Chinthrajah RS, Nadeau KC, Galli SJ. Sustained
successful peanut oral immunotherapy associated with low basophil
activation and peanut-specific IgE. J Allergy Clin Immunol.2020;145(3):885-896 e886.
21. Behrends J, Schwager C, Hein M, Scholzen T, Kull S, Jappe U.
Innovative robust basophil activation test using a novel gating strategy
reliably diagnosing allergy with full automation. Allergy.2021;76(12):3776-3788.
22. Santos AF, Kulis MD, Sampson HA. Bringing the Next Generation of
Food Allergy Diagnostics Into the Clinic. J Allergy Clin Immunol
Pract. 2022;10(1):1-9.
23. Monino-Romero S, Lexmond WS, Singer J, et al. Soluble
FcvarepsilonRI: A biomarker for IgE-mediated diseases. Allergy.2019;74(7):1381-1384.
24. Breiteneder H, Peng YQ, Agache I, et al. Biomarkers for diagnosis
and prediction of therapy responses in allergic diseases and asthma.Allergy. 2020;75(12):3039-3068.
25. Ogulur I, Pat Y, Ardicli O, et al. Advances and highlights in
biomarkers of allergic diseases. Allergy. 2021;76(12):3659-3686.
26. Ehlers AM, den Hartog Jager CF, Knulst AC, Otten HG. Distinction
between peanut allergy and tolerance by characterization of B cell
receptor repertoires. Allergy. 2021;76(9):2753-2764.
27. Arasi S, Nurmatov U, Dunn-Galvin A, et al. Consensus on DEfinition
of Food Allergy SEverity (DEFASE) an integrated mixed methods systematic
review. World Allergy Organ J. 2021;14(3):100503.
28. Dribin TE, Schnadower D, Spergel JM, et al. Severity grading system
for acute allergic reactions: A multidisciplinary Delphi study. J
Allergy Clin Immunol. 2021;148(1):173-181.
29. Burks AW, Jones SM, Wood RA, et al. Oral immunotherapy for treatment
of egg allergy in children. N Engl J Med. 2012;367(3):233-243.
30. Chinthrajah RS, Jones SM, Kim EH, et al. Updating the CoFAR Grading
Scale for Systemic Allergic Reactions in Food Allergy. J Allergy
Clin Immunol. 2022.
31. Fernandez-Rivas M, Gomez Garcia I, Gonzalo-Fernandez A, et al.
Development and validation of the Food Allergy Severity Score.Allergy. 2021.
32. Purington N, Chinthrajah RS, Long A, et al. Eliciting Dose and
Safety Outcomes From a Large Dataset of Standardized Multiple Food
Challenges. Front Immunol. 2018;9:2057.
33. Chinthrajah RS, Purington N, Andorf S, et al. Development of a tool
predicting severity of allergic reaction during peanut challenge.Ann Allergy Asthma Immunol. 2018;121(1):69-76 e62.
34. Patel N, Adelman DC, Anagnostou K, et al. Using data from food
challenges to inform management of consumers with food allergy: A
systematic review with individual participant data meta-analysis.J Allergy Clin Immunol. 2021;147(6):2249-2262 e2247.
35. Turner PJ, Patel N, Ballmer-Weber BK, et al. Peanut Can Be Used as a
Reference Allergen for Hazard Characterization in Food Allergen Risk
Management: A Rapid Evidence Assessment and Meta-Analysis. J
Allergy Clin Immunol Pract. 2022;10(1):59-70.
36. Du Toit G, Roberts G, Sayre PH, et al. Randomized trial of peanut
consumption in infants at risk for peanut allergy. N Engl J Med.2015;372(9):803-813.
37. Fleischer DM, Sicherer S, Greenhawt M, et al. Consensus
Communication on Early Peanut Introduction and Prevention of Peanut
Allergy in High-Risk Infants. Pediatr Dermatol.2016;33(1):103-106.
38. Azad MB, Dharma C, Simons E, et al. Reduced peanut sensitization
with maternal peanut consumption and early peanut introduction while
breastfeeding. J Dev Orig Health Dis. 2021;12(5):811-818.
39. Rosario Filho N. [Early introduction of food to prevent food
allergy. The LEAP study (Learning Early about Peanut)]. Rev Paul
Pediatr. 2015;33(4):493-494.
40. Du Toit G, Sampson HA, Plaut M, Burks AW, Akdis CA, Lack G. Food
allergy: Update on prevention and tolerance. J Allergy Clin
Immunol. 2018;141(1):30-40.
41. du Toit G, Sayre PH, Roberts G, et al. Allergen specificity of early
peanut consumption and effect on development of allergic disease in the
Learning Early About Peanut Allergy study cohort. J Allergy Clin
Immunol. 2018;141(4):1343-1353.
42. Yakaboski E, Robinson LB, Arroyo A, et al. Early Introduction of
Food Allergens and Risk of Developing Food Allergy. Nutrients.2021;13(7).
43. Marques-Mejias MA, Fisher H, Lack G, Du Toit G. Translating research
into practice: What’s new in the 2021 EAACI food allergy prevention
guidelines? Clin Exp Allergy. 2022;52(4):476-480.
44. Sakihara T, Otsuji K, Arakaki Y, Hamada K, Sugiura S, Ito K.
Randomized trial of early infant formula introduction to prevent cow’s
milk allergy. J Allergy Clin Immunol. 2021;147(1):224-232 e228.
45. Holl JL, Bilaver LA, Finn DJ, Savio K. A randomized trial of the
acceptability of a daily multi-allergen food supplement for infants.Pediatr Allergy Immunol. 2020;31(4):418-420.
46. Krawiec M, Fisher HR, Du Toit G, Bahnson HT, Lack G. Overview of
oral tolerance induction for prevention of food allergy-Where are we
now? Allergy. 2021;76(9):2684-2698.
47. Amazouz H, de Lauzon-Guillain B, Bourgoin-Heck M, et al. Infant
feeding clusters are associated with respiratory health and allergy at
school age in the PARIS birth cohort. Allergy.2021;76(4):1223-1234.
48. Adjibade M, Davisse-Paturet C, Bernard JY, et al. Enrichment of
infant formula with long-chain polyunsaturated fatty acids and risk of
infection and allergy in the nationwide ELFE birth cohort.Allergy. 2021.
49. Brough HA, Nadeau KC, Sindher SB, et al. Epicutaneous sensitization
in the development of food allergy: What is the evidence and how can
this be prevented? Allergy. 2020;75(9):2185-2205.
50. Warnberg Gerdin S, Lie A, Asarnoj A, et al. Impaired skin barrier
and allergic sensitization in early infancy. Allergy. 2021.
51. Mortz CG, du Toit G, Beyer K, et al. When and how to evaluate for
immediate type food allergy in children with atopic dermatitis.Allergy. 2021;76(12):3845-3848.
52. Sindher S, Alkotob SS, Shojinaga MN, et al. Pilot study measuring
transepidermal water loss (TEWL) in children suggests trilipid cream is
more effective than a paraffin-based emollient. Allergy.2020;75(10):2662-2664.
53. Sindher S, Alkotob SS, Shojinaga MN, et al. Increases in plasma
IgG4/IgE with trilipid vs paraffin/petrolatum-based emollients for dry
skin/eczema. Pediatr Allergy Immunol. 2020;31(6):699-703.
54. Zhong Y, Samuel M, van Bever H, Tham EH. Emollients in infancy to
prevent atopic dermatitis: A systematic review and meta-analysis.Allergy. 2021.
55. Brough HA, Lanser BJ, Sindher SB, et al. Early intervention and
prevention of allergic diseases. Allergy. 2022;77(2):416-441.
56. Chalmers JR, Haines RH, Bradshaw LE, et al. Daily emollient during
infancy for prevention of eczema: the BEEP randomised controlled trial.Lancet. 2020;395(10228):962-972.
57. Perkin MR, Logan K, Marrs T, et al. Association of frequent
moisturizer use in early infancy with the development of food allergy.J Allergy Clin Immunol. 2021;147(3):967-976 e961.
58. Lowe AJ, Su JC, Allen KJ, et al. A randomized trial of a barrier
lipid replacement strategy for the prevention of atopic dermatitis and
allergic sensitization: the PEBBLES pilot study. Br J Dermatol.2018;178(1):e19-e21.
59. Sampath V, Sindher SB, Alvarez Pinzon AM, Nadeau KC. Can food
allergy be cured? What are the future prospects? Allergy.2020;75(6):1316-1326.
60. de Silva D, Rodriguez Del Rio P, de Jong NW, et al. Allergen
immunotherapy and/or biologicals for IgE-mediated food allergy: A
systematic review and meta-analysis. Allergy. 2022.
61. Eiwegger T, Hung L, San Diego KE, O’Mahony L, Upton J. Recent
developments and highlights in food allergy. Allergy.2019;74(12):2355-2367.
62. Yu S, Smith A, Hass S, et al. The Risk Reduction of Accidental
Exposure-Related Systemic Allergic Reactions Extrapolated Based on Food
Challenge Data After 1 Year of Peanut Oral Immunotherapy. Adv
Ther. 2021;38(8):4321-4332.
63. Investigators PGoC, Vickery BP, Vereda A, et al. AR101 Oral
Immunotherapy for Peanut Allergy. N Engl J Med.2018;379(21):1991-2001.
64. Vickery BP, Vereda A, Nilsson C, et al. Continuous and Daily Oral
Immunotherapy for Peanut Allergy: Results from a 2-Year Open-Label
Follow-On Study. J Allergy Clin Immunol Pract.2021;9(5):1879-1889 e1814.
65. Kim EH, Burks AW. Food allergy immunotherapy: Oral immunotherapy and
epicutaneous immunotherapy. Allergy. 2020;75(6):1337-1346.
66. Bajzik V, DeBerg HA, Garabatos N, et al. Oral desensitization
therapy for peanut allergy induces dynamic changes in peanut-specific
immune responses. Allergy. 2022.
67. Elizur A, Appel MY, Nachshon L, et al. Cashew oral immunotherapy for
desensitizing cashew-pistachio allergy (NUT CRACKER study).Allergy. 2022.
68. Epstein-Rigbi N, Goldberg MR, Levy MB, Nachshon L, Elizur A. Quality
of life of children aged 8-12 years undergoing food allergy oral
immunotherapy: Child and parent perspective. Allergy.2020;75(10):2623-2632.
69. Dunn Galvin A, McMahon S, Ponsonby AL, Hsiao KC, Tang MLK, team Ps.
The longitudinal impact of probiotic and peanut oral immunotherapy on
health-related quality of life. Allergy. 2018;73(3):560-568.
70. Rigbi NE, Goldberg MR, Levy MB, Nachshon L, Golobov K, Elizur A.
Changes in patient quality of life during oral immunotherapy for food
allergy. Allergy. 2017;72(12):1883-1890.
71. Jones SM, Kim EH, Nadeau KC, et al. Efficacy and safety of oral
immunotherapy in children aged 1-3 years with peanut allergy (the Immune
Tolerance Network IMPACT trial): a randomised placebo-controlled study.Lancet. 2022;399(10322):359-371.
72. Fleischer DM, Greenhawt M, Sussman G, et al. Effect of Epicutaneous
Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among
Children With Peanut Allergy: The PEPITES Randomized Clinical Trial.JAMA. 2019;321(10):946-955.
73. Scurlock AM, Burks AW, Sicherer SH, et al. Epicutaneous
immunotherapy for treatment of peanut allergy: Follow-up from the
Consortium for Food Allergy Research. J Allergy Clin Immunol.2021;147(3):992-1003 e1005.
74. Fleischer DM, Shreffler WG, Campbell DE, et al. Long-term,
open-label extension study of the efficacy and safety of epicutaneous
immunotherapy for peanut allergy in children: PEOPLE 3-year results.J Allergy Clin Immunol. 2020;146(4):863-874.
75. Fleischer DM, Chinthrajah S, Scurlock AM, et al. An evaluation of
factors influencing response to epicutaneous immunotherapy for peanut
allergy in the PEPITES trial. Allergy Asthma Proc.2020;41(5):326-335.
76. Narisety SD, Frischmeyer-Guerrerio PA, Keet CA, et al. A randomized,
double-blind, placebo-controlled pilot study of sublingual versus oral
immunotherapy for the treatment of peanut allergy. J Allergy Clin
Immunol. 2015;135(5):1275-1282 e1271-1276.
77. Tomsitz D, Biedermann T, Brockow K. Sublingual immunotherapy reduces
reaction threshold in three patients with wheat-dependent
exercise-induced anaphylaxis. Allergy. 2021;76(12):3804-3806.
78. Kim EH, Yang L, Ye P, et al. Long-term sublingual immunotherapy for
peanut allergy in children: Clinical and immunologic evidence of
desensitization. J Allergy Clin Immunol. 2019;144(5):1320-1326
e1321.
79. Savage JH, Lee-Sarwar KA, Sordillo J, et al. A prospective
microbiome-wide association study of food sensitization and food allergy
in early childhood. Allergy. 2018;73(1):145-152.
80. Fazlollahi M, Chun Y, Grishin A, et al. Early-life gut microbiome
and egg allergy. Allergy. 2018;73(7):1515-1524.
81. He Z, Vadali VG, Szabady RL, et al. Increased diversity of gut
microbiota during active oral immunotherapy in peanut-allergic adults.Allergy. 2021;76(3):927-930.
82. Loke P, Orsini F, Lozinsky AC, et al. Probiotic peanut oral
immunotherapy versus oral immunotherapy and placebo in children with
peanut allergy in Australia (PPOIT-003): a multicentre, randomised,
phase 2b trial. Lancet Child Adolesc Health. 2022;6(3):171-184.
83. Jing W, Liu Q, Wang W. Bifidobacterium bifidum TMC3115 ameliorates
milk protein allergy in by affecting gut microbiota: A randomized
double-blind control trial. J Food Biochem. 2020;44(11):e13489.
84. Sindher SB, Kumar D, Cao S, et al. Phase 2, randomized multi oral
immunotherapy with omalizumab ’real life’ study. Allergy. 2022.
85. Azzano P, Paquin M, Langlois A, et al. Determinants of omalizumab
dose-related efficacy in oral immunotherapy: Evidence from a cohort of
181 patients. J Allergy Clin Immunol. 2021;147(1):233-243.
86. Begin P, Dominguez T, Wilson SP, et al. Phase 1 results of safety
and tolerability in a rush oral immunotherapy protocol to multiple foods
using Omalizumab. Allergy Asthma Clin Immunol. 2014;10(1):7.
87. Andorf S, Purington N, Block WM, et al. Anti-IgE treatment with oral
immunotherapy in multifood allergic participants: a double-blind,
randomised, controlled trial. Lancet Gastroenterol Hepatol.2018;3(2):85-94.
88. Manohar M, Dunham D, Gupta S, et al. Immune changes beyond Th2
pathways during rapid multifood immunotherapy enabled with omalizumab.Allergy. 2021;76(9):2809-2826.
89. Andorf S, Purington N, Kumar D, et al. A Phase 2 Randomized
Controlled Multisite Study Using Omalizumab-facilitated Rapid
Desensitization to Test Continued vs Discontinued Dosing in Multifood
Allergic Individuals. EClinicalMedicine. 2019;7:27-38.
90. Wood RA, Kim JS, Lindblad R, et al. A randomized, double-blind,
placebo-controlled study of omalizumab combined with oral immunotherapy
for the treatment of cow’s milk allergy. J Allergy Clin Immunol.2016;137(4):1103-1110 e1111.
91. Sampson HA, Leung DY, Burks AW, et al. A phase II, randomized,
doubleblind, parallelgroup, placebocontrolled oral food challenge trial
of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol.2011;127(5):1309-1310 e1301.
92. Nadeau KC, Schneider LC, Hoyte L, Borras I, Umetsu DT. Rapid oral
desensitization in combination with omalizumab therapy in patients with
cow’s milk allergy. J Allergy Clin Immunol.2011;127(6):1622-1624.
93. Bedoret D, Singh AK, Shaw V, et al. Changes in antigen-specific
T-cell number and function during oral desensitization in cow’s milk
allergy enabled with omalizumab. Mucosal Immunol.2012;5(3):267-276.
94. Gasser P, Tarchevskaya SS, Guntern P, et al. The mechanistic and
functional profile of the therapeutic anti-IgE antibody ligelizumab
differs from omalizumab. Nat Commun. 2020;11(1):165.
95. Gauvreau GM, Arm JP, Boulet LP, et al. Efficacy and safety of
multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in
inhibiting allergen-induced early asthmatic responses. J Allergy
Clin Immunol. 2016;138(4):1051-1059.
96. Arm JP, Bottoli I, Skerjanec A, et al. Pharmacokinetics,
pharmacodynamics and safety of QGE031 (ligelizumab), a novel
high-affinity anti-IgE antibody, in atopic subjects. Clin Exp
Allergy. 2014;44(11):1371-1385.
97. Hirano I, Dellon ES, Hamilton JD, et al. Efficacy of Dupilumab in a
Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis.Gastroenterology. 2020;158(1):111-122 e110.
98. Warren CM, Jiang J, Gupta RS. Epidemiology and Burden of Food
Allergy. Curr Allergy Asthma Rep. 2020;20(2):6.
99. O’Loughlin R, Hiscock H. Presentations to emergency departments by
children and young people with food allergy are increasing. Med J
Aust. 2020;213(1):27-29.